Clean Yield Group Decreases Stake in Novo Nordisk A/S (NYSE:NVO)

Clean Yield Group lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 2.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,076 shares of the company’s stock after selling 800 shares during the quarter. Clean Yield Group’s holdings in Novo Nordisk A/S were worth $2,297,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. boosted its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its position in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. Transce3nd LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $33,000. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Friday. Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $128.00.

Novo Nordisk A/S Price Performance

NVO stock opened at $74.70 on Friday. The stock has a market capitalization of $335.22 billion, a price-to-earnings ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The stock’s fifty day simple moving average is $65.87 and its 200-day simple moving average is $80.54.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The firm had revenue of $11.87 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.